Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A RANDOMIZED COMPARATIVE STUDY ASSESSING THE SWITCHING BETWEEN PF-06410293 AND HUMIRA (REGISTERED) IN COMBINATION WITH METHOTREXATE IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS

NCT04230213 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04230213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04230213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A RANDOMIZED COMPARATIVE STUDY ASSESSING THE SWITCHING BETWEEN PF-06410293 AND HUMIRA (REGISTERED) IN COMBINATION WITH METHOTREXATE IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
January 13, 2020
Completion date
June 22, 2021
Enrollment
455 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis